Table 5.
Regimen | Cases (%) |
---|---|
Single agent topotecan | 38 (37.3) |
Combined regimen containing topotecan | 16 (15.7) |
EP | 17 (16.7) |
CE | 6 (5.9) |
IP | 9 (8.8) |
CAV | 2 (1.9) |
Single agent etoposide or teniposide | 2 (1.9) |
Other regimens | 12 (11.8) |
EP, etoposide with cisplatin; CAV, cyclophosphamide/adriamycin/vincristine; CE, etoposide with carboplatin; IP, irinotecan/cisplatin.